Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Inks Southeast Asian Marketing Deal for Breast Cancer Tests

NEW YORK (GenomeWeb) – Agendia said today that it has signed a marketing agreement with Angsana Molecular & Diagnostics Laboratory for Agendia's MammaPrint and BluePrint breast cancer tests in Southeast Asia.

MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.

Under the terms of the deal, diagnostic developer Angsana will market the tests to physicians in Singapore, Malaysia, Vietnam, Brunei, and Myanmar.  

Additional terms were not disclosed.

"Southeast Asia represents a significant growth opportunity for Agendia and a commercial priority for the company," Agendia Chief Commercial Officer Chris Barbazette said in a statement. "With their extensive experience in molecular diagnostics and regional insight, Angsana is an ideal partner as we continue to build our presence in this rapidly evolving market."

In addition to its own diagnostics, Singapore-based Angsana offers tests from Admera Health and Counsyl in Asia.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.